首页> 美国卫生研究院文献>Mayo Clinic Proceedings >New Developments in the Medical Management of Prostate Cancer
【2h】

New Developments in the Medical Management of Prostate Cancer

机译:前列腺癌医疗管理的新发展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prostate cancer is a substantial public health burden and a leading cause of cancer—related morbidity and mortality in the United States despite the observation that annual prostate cancer—specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.
机译:前列腺癌是巨大的公共卫生负担,并且是美国癌症相关发病率和死亡率的主要原因,尽管观察到每年前列腺癌的特定死亡率在过去十年中一直在下降。尽管尚不清楚这种积极发展的原因,但可能综合了多种因素。本更新将根据对前列腺癌生物学的最新理解,回顾正在进行的发展并总结前列腺癌治疗的治疗进展。该综述的文献于2009年通过在PubMed中搜索以下关键字来选择:前列腺肿瘤,去势,雄激素受体,激素和化疗。在过去的5至10年中,重点放在已发表的晚期前列腺癌治疗药物的临床研究中。该评价中还包括针对发展中的前列腺癌目前正在开发的靶向雄激素受体的新型激素药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号